J.-M. Nabholtz
- Oncology top 5%
- Cancer Treatment and Pharmacology 14
- HER2/EGFR in Cancer Research 7
- Neutropenia and Cancer Infections 3
- Peptidase Inhibition and Analysis 3
- Colorectal Cancer Treatments and Studies 3
- Cancer Research top 10%
- Breast Cancer Treatment Studies 12
- Dermatology top 10%
-
- Estrogen and related hormone effects 3
-
- Chemotherapy-induced cardiotoxicity and mitigation 3
- Co-authors
- P. FumoleauM. NamerBenjamin WinogradG. CatimelM. SpielmannM. BontenbalPierfranco ContéJacques Bonneterre
- Cited by
- OncologyCancer ResearchDermatology
- Journals
- Journal of Clinical Oncology (6 papers)European Journal of Cancer (7 papers)The Oncologist (1 paper)
- Partner nations
- CanadaFranceUnited States
In The Last Decade
J.-M. Nabholtz
23 papers receiving 711 citations
Peers
Comparison fields: 5 of 72
- Oncology 518
- Cancer Research 209
- Dermatology 71
- Hematology 56
- Immunology 103
Countries citing papers authored by J.-M. Nabholtz
This map shows the geographic impact of J.-M. Nabholtz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.-M. Nabholtz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.-M. Nabholtz more than expected).
Fields of papers citing papers by J.-M. Nabholtz
This network shows the impact of papers produced by J.-M. Nabholtz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.-M. Nabholtz. The network helps show where J.-M. Nabholtz may publish in the future.
Co-authorship network
The 25 scholars most cited alongside J.-M. Nabholtz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 8 | |
| 2 | 2015 | 49 | |
| 3 | 2013 | 5 | |
| 4 | 2011 | 1 | |
| 5 | 2011 | 13 | |
| 6 | 2010 | 5 | |
| 7 | 2010 | 1 | |
| 8 | 2008 | 51 | |
| 9 | 2006 | 5 | |
| 10 | Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. | 2000 | 26 |
| 11 | An epidemiological review of red cell transfusions in cancer chemotherapy. | 1999 | 15 |
| 12 | 1998 | 1 | |
| 13 | 1997 | 4 | |
| 14 | Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. | 1997 | 31 |
| 15 | Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer. | 1997 | 24 |
| 16 | 1997 | 5 | |
| 17 | 1996 | 331 | |
| 18 | 1995 | 7 | |
| 19 | 1993 | 155 | |
| 20 | 1993 | 1 |
About J.-M. Nabholtz
J.-M. Nabholtz is a scholar working on Cancer Research, Oncology and Hematology, having authored 24 papers that have together received 742 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (14 papers), Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (7 papers), Neutropenia and Cancer Infections (3 papers), Estrogen and related hormone effects (3 papers), Peptidase Inhibition and Analysis (3 papers), Chemotherapy-induced cardiotoxicity and mitigation (3 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Oncology (518 citations), Cancer Research (209 citations) and Dermatology (71 citations). J.-M. Nabholtz has collaborated with scholars based in Canada, France and United States. Frequent co-authors include P. Fumoleau, M. Namer, Benjamin Winograd, G. Catimel, M. Spielmann, M. Bontenbal, Pierfranco Conté, Jacques Bonneterre, Karen A. Gelmon and U. Klaassen. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.